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Background and Aims. Complementary and alternative medicine (CAM) is commonly used among patients with inﬂammatory
bowel diseases (IBD), but evidence about its real-life use is limited. We aimed to assess and compare CAM use in outpatients
with IBD and other gastrointestinal diseases. Materials and Methods. The use of herbs and botanicals, lifestyle modiﬁcations and
mind/body therapies, patient satisfaction, and continuous use of conventional medicine were assessed with an anonymous
questionnaire at a tertiary IBD unit in Hungary. 396 IBD patients (207 with Crohn’s disease, 185 with ulcerative colitis, and 4
with indeterminate colitis) and 164 patients with gastric acid-related diseases, premalignant and malignant colorectal diseases,
lactose intolerance, celiac disease, dysbacteriosis, and so on were included. Results. IBD patients reported signiﬁcantly lower
usage of herbs than did controls (25% versus 42%, p < 0 001). More than 90% of responding IBD patients continued
conventional medication besides herbal remedies (83% in unaltered doses). IBD patients were more likely to implement lifestyle
modiﬁcations (77% versus 63%, p = 0 0011), but not body/mind therapies (20% versus 15%, p = 0 1516). Younger age was a
signiﬁcant predictor of lifestyle modiﬁcations (p = 0 0246). Conclusions. CAM use (especially that of herbal remedies) in IBD is
less frequent than that in other gastrointestinal diseases. It is more a complementary than an alternative to conventional
medicine in IBD. There is no signiﬁcant diﬀerence between CAM use in patients with Crohn’s disease and that in patients with
ulcerative colitis, although the latter tend to choose herbs; the beneﬁt of which is supported by scientiﬁc evidence. This study is
registered at the Medical Research Council, Hungary. This trial is registered with 3769/2010/1018EKU.
1. Introduction
Inﬂammatory bowel diseases (IBD) including Crohn’s dis-
ease (CD) and ulcerative colitis (UC) have a signiﬁcant
impact on health-related quality of life [1]. Besides the debil-
itating symptoms of relapses, psychological distress associ-
ated with unpredictable disease course and development of
complications and adverse events related to medication often
occurs during remission [2, 3]. The desire to gain more con-
trol over IBD and to be treated as a whole person might lead
patients to unconventional treatment methods.
Complementary and alternative medicine (CAM) is an
umbrella term for a set of health care practices that are not
part of a country’s traditional medical practices and are not
integrated into the dominant health care system. Generally,
alternative medicine refers to methods that replace tradi-
tional treatments, while complementary medicine involves
those that are used as an addition to conventional therapy.
CAM use seems to be increasing in recent decades. Accord-
ing to a recent survey, it is around 40% in chronic gastroin-
testinal conditions and varies between 20 and 60% in IBD
as a special subgroup of the previous [3–7].
Hindawi
Gastroenterology Research and Practice
Volume 2018, Article ID 9137805, 8 pages
https://doi.org/10.1155/2018/9137805
The aim of this study was to examine the frequency and
predictors of regular CAM use in IBD patients and to com-
pare data with the one obtained from patients diagnosed with
other chronic gastrointestinal diseases.
2. Methods
An anonymous questionnaire was distributed to outpatients
at a tertiary IBD unit in Szeged, Hungary, between February
and October 2015. Patients were categorized as suﬀering
from IBD (CD, UC, and indeterminate colitis) or any other
chronic gastrointestinal disease (control group: gastric
acid-related diseases [reﬂux disease, gastric or duodenal
ulcer, etc.], irritable bowel syndrome, celiac disease, lactose
intolerance, colorectal diseases [e.g., diverticulosis or malig-
nancies], and other). The survey focused on the use of herbs
and botanicals, lifestyle modiﬁcations (exercise, diet, or
cessation of smoking), and mind/body therapies (stress man-
agement, relaxation techniques [autogenic training, brain
control, meditation, and hypnotherapy], massage, kinesiol-
ogy, yoga, acupuncture, etc.). Frequency of CAM use, patient
satisfaction, and continuous use of conventional medicine
were assessed in each category. The study was registered at
the Medical Research Council, Hungary, with the registration
identiﬁcation number 3769/2010/1018EKU and was con-
ducted in accordance with the principles of the Declaration
of Helsinki.
2.1. Statistical Analysis. Categorical variables are presented
as percentages and are compared among groups using
Fisher’s exact test. Multivariate analysis to investigate pre-
dictors of CAM usage was performed with penalized logistic
regression, controlling for age, sex, concurrent conven-
tional medication, and disease duration. Age and disease
duration were entered into the model with restricted
cubic spline expansion to allow for a ﬂexible functional
form; however, no interaction was allowed between the
variables. The necessity of nonlinearity was checked with
a joint F-test on nonlinear terms (prespeciﬁed test), and
a linear model was speciﬁed if p < 0 05 in this test. Penalty
was chosen to optimize Hurvich and Tsai’s corrected AIC
[8]. Statistical analysis was performed under R program
package version 3.3.2 [9] with a custom script that is available
at the corresponding author on request using library rms ver-
sion 5.1-0 [10].
3. Results
396 consecutive IBD patients (207 with CD, 185 with UC,
and 4 with indeterminate colitis; mean age: 42 years; male/
female ratio: 183/205 ([8] patients gave no answer); mean
disease duration: 11 years) and 164 patients with other
chronic gastrointestinal diseases (gastric acid-related diseases
[N = 56], premalignant and malignant colorectal diseases
[N = 33], diverticulosis and irritable bowel syndrome [N = 22],
lactose intolerance [N = 11], celiac disease [N = 12], and
dysbacteriosis and other [N = 30]; mean age: 53 years;
male/female ratio: 40/124; mean disease duration: 5 years)
were included in our study. 92% of IBD patients (N = 364)
were taking medication (5-aminosalicylates, corticosteroids,
immunomodulatory drugs, antibiotics, or biologics) for
their IBD at the time of the survey, while only 35% of con-
trol patients (N = 58) were on drugs (proton pump inhibi-
tors, antibiotics, prokinetics, spasmolytic and analgesic
drugs, and digestive enzymes) (Figure 1).
Total CAM use (including any of herbs/botanicals, life-
style changes, and mind/body therapies) was 80% among
IBD patients and 74% in the control group (p = 0 141).
Almost two-thirds of CAM users applied at least two
methods simultaneously (62% and 65% for IBD and control
patients, resp.) (range: 1–9). In the IBD group, there was
no signiﬁcant diﬀerence between total CAM use of patients
with CD and that of patients with UC (79% and 83%,
p = 0 4407). There was no signiﬁcant diﬀerence between
the two phenotypes of IBD regarding the use of herbal
remedies (p = 0 1033), lifestyle modiﬁcations (p = 1), or
body/mind therapies (p = 0 6147).
3.1. Herbs and Botanicals. IBD patients reported signiﬁcantly
lower use of herbal remedies than did controls (25% versus
42%, p < 0 001) (Figure 2) and were more likely to use a
single herbal product (62% versus 52%). Aloe vera was
the most popular in both groups: 24% and 32% of those
administering herbs reported its use (Table 1). The majority
of patients were satisﬁed with the products (Figure 3(a)).
More than 90% of IBD patients continued their conventional
medication, and 83% of the responders did it so by maintain-
ing the original dose. Continuation rates of conventional
therapies were similar, although somewhat lower in the con-
trol group (Figure 4(a)).
Usage rates of herbs and botanicals were similar in CD
and UC patients (25% and 29%), with nearly two-thirds of
them administering a single product (63% and 61%, resp.)
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Figure 1: Concurrent medication in the IBD (a) and control group (b). IBD: inﬂammatory bowel diseases.
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(Figure 5). Aloe vera was the most commonly used in both
IBD groups (18% of CD patients and 28% of UC patients
reported its use). Interestingly, milk thistle was almost ﬁve
times as popular among patients with UC as among those
with CD (Table 1). Generally, both CD and UC patients
considered herbal remedies beneﬁcial, and only one patient
with Crohn’s disease reported aversion towards their use
(Figure 6(a)). A total of 6 IBD patients reported cessation
of conventional medication (3 patients with CD and 3
patients with UC), and 83% of patients continued with the
conventional IBD therapy in both groups (Figure 6(b)).
3.2. Lifestyle Modiﬁcations. IBD patients were more likely to
implement lifestyle modiﬁcations after the diagnosis com-
pared to the control group (77% versus 63%, p = 0 0011)
(Figure 2). The high rate was mainly attributable to dietary
changes in both groups (70% versus 57% in the IBD group
and control group, resp.). More than 20% of patients started
regular exercise (29% versus 20%), and more than 7% of
them stopped smoking. Interestingly, three times as many
patients with CD as those with UC quitted smoking (30 ver-
sus 11). No such diﬀerence could be observed between IBD
subgroups regarding dietary changes and exercise (Table 1).
None of the patients reported aversion to lifestyle changes,
and only 15 IBD (9 with CD and 6 with UC) and 2 control
patients were neutral.
3.3. Mind and Body Therapies. 20% of IBD and 15% of con-
trol patients (p = 0 1516) used mind/body therapies
(Figure 2). In both groups, patients preferred relaxation tech-
niques the most (Table 1) and were likely to stick with one
technique at a time (68% and 58% for the IBD group and
control group, resp.). 80% and 78% of the responders in each
group were satisﬁed with the applied mind/body therapy,
and only two patients (one with CD and one with reﬂux dis-
ease) reported negative opinion about stress management
techniques (Figure 3(b)). Only ﬁve IBD (3 with CD and 2
with UC) patients stopped their conventional medication
after starting a mind/body technique, and 85% of the
responders continued with traditional IBD therapy in
unchanged doses. This rate was only 67% for the control
group, but a low case number may prevent reliable assess-
ment (Figure 4(b)).
3.4. Multivariate Analysis of Predictive Factors. Patients with
indeterminate colitis were not investigated in the multivar-
iate model due to their low count. In the multivariate
model, neither female gender (p = 0 0763), nor younger
age (p = 0 3326), nor disease duration (p = 0 4227) predicted
the use of herbs and botanicals; however, IBD patients were
signiﬁcantly less likely to use this modality (OR=0.58 [95%
CI: 0.38–0.88], p = 0 0097). Younger age was found to be a
signiﬁcant predictor of lifestyle modiﬁcation (p = 0 0246), but
not the usage of mind/body therapies (p = 0 3425). None of
female gender, disease duration, or IBD predicted the use
of these CAMs (p = 0 6295, p = 0 0847, and p = 0 1172 for
lifestyle changes and p = 0 5825, p = 0 3018, and p = 0 5246
for mind/body therapies). In an extended model for the
IBD group that included disease phenotype, steroid intake,
and usage and kind of biological therapy in addition to
age, sex, and disease duration, none was found to be associ-
ated with herbal therapy, lifestyle modiﬁcation, or mind/
body therapies.
4. Discussion
CAM use is around 50% in developed countries and over
80% in underdeveloped countries [11] with a substantial rise
in Europe over the last two decades [12]. In case of chronic
gastrointestinal conditions, especially functional disorders,
this rate is around 40% [5]. In IBD, a special subgroup of
the above, it varies between 20% and 60%, and occasional
CAM use might be as high as 81% [3, 4, 6, 7, 13]. Variations
in usage rates and the most common CAM types might be
attributable to ambiguous deﬁnition (e.g., acupuncture is
considered CAM in Europe, whereas it is a traditional
method in Asia) and inconsistent inclusion criteria of CAM
(e.g., vitamins, exercise, and prayer) [4, 14]. These variations
are reﬂected in our study too; usage rates of diﬀerent CAM
types showed signiﬁcant diﬀerences in both groups. Given
the fact that multiple CAM use is a common phenomenon
[4, 6], CAM options can hardly be evaluated on their own.
4.1. Herbs and Botanicals. Herbal remedies are among the
most popular and well-studied CAM options. According to
a Canadian nationwide survey among IBD patients, herbs
were most frequently administered (41%) [4]. A recent
meta-analysis provided evidence about the eﬃcacy of anti-
inﬂammatory Aloe vera in UC of mild-to-moderate activity,
the beneﬁcial eﬀects of wheat grass juice in proctitis, and
the feasibility of curcumin and Plantago ovata in maintaining
remission in UC (the latter was reported to be of similar
eﬃcacy as mesalazine) [15]. According to a recent review of
controlled trials investigating herbal products in IBD, Andro-
graphis paniculata (Indian Echinacea), Boswellia serrata, and
topical Xilei-San might also be useful in active UC, and a
mixture of myrrh, chamomile ﬂower extract, coﬀee charcoal,
and milk thistle can also be beneﬁcial in inactive UC for
maintaining remission [16]. Regarding CD, a smaller num-
ber of clinical trials were conducted, most of them with poor
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Figure 2: Frequency of CAM use in the IBD and control group.
CAM: complementary and alternative medicine; IBD: inﬂammatory
bowel diseases.
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design and small case number. Nevertheless, wormwood and
Boswellia serrata showed promising results for active CD,
and Tripterygium wilfordii can have a potential beneﬁt in
inactive CD for the prevention of relapses [15, 16]. Our study
revealed that there was no signiﬁcant diﬀerence between the
types of herbs used by UC and CD patients, although more
UC than CD patients chose Aloe vera, milk thistle, curcumin,
and wheatgrass. This might reﬂect potential patient aware-
ness of the beneﬁcial eﬀect of these products on UC. On
the other hand, no use of wormwood, Boswellia serrata, or
Tripterygium wilfordii was reported by CD patients, suggest-
ing less awareness of these herbs. However, this fact did not
seem to alter patient satisfaction with the administered
herbal product(s), nor continuation rates of conventional
IBD medication (Figure 6).
It should be highlighted that reliable data on the eﬃcacy
of herbs is still limited, and potential adverse events and
interactions with conventional medications should also be
noted [3]. Although the most commonly used herbal prod-
ucts in our study (Table 1)—except for medicinal fungi—are
not among those reportedwithahepatotoxic eﬀect [17], health
care professionals should be aware of the potential hepato-
toxicity of herbs, especially in the case of IBD-associated
liver diseases.
Table 1: The most preferred CAM types.
IBD∗ (N = 396) CD (N = 207) UC (N = 185) Control group (N = 164)
Herbs and botanicals
Aloe vera 24 9 15 22
Milk thistle 11 2 9 13
Walnut leaf 11 7 4 0
Curcumin 10 4 6 14
Wheatgrass 9 3 6 9
Plantago ovata 7 3 4 4
Medicinal fungi 7 3 4 1
Chamomile 6 5 1 4
Lifestyle changes
Special diet 279 146 133 94
Exercise 112 64 48 32
Cessation of smoking 41 30 11 12
Mind/body therapies
Relaxation techniques 36 18 17 16
Stress management 28 16 12 7
Kinesiology, yoga, massage 23 15 7 7
Acupuncture 16 7 8 4
∗ includes patients with Crohn’s disease (CD), ulcerative colitis (UC), and indeterminate colitis. CAM: complementary and alternative medicine;
IBD: inﬂammatory bowel diseases.
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Figure 3: Patient opinions about herbs and botanicals (a) and mind/body therapies (b). IBD: inﬂammatory bowel diseases.
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The signiﬁcantly lower use of herbs in IBD compared to
other gastrointestinal conditions—considering the high
usage and continuation rates of traditional IBD medications
as well—suggests remarkable trust in conventional therapy
and more profound knowledge about the disease and also
reﬂects fear of relapses and complications. Our study was
conducted in a tertiary IBD center; hence, patient selection
can possibly lead to biases as patients attending specialized
clinics tend to have more trust in conventional medicine
compared to the general population [4]. According to
Nguyen et al., only CAM applied for IBD treatment (and
not for the general well-being) impairs adherence to tradi-
tional medication [18].
4.2. Lifestyle Changes. It is debatable whether lifestyle
changes should be deﬁned as CAM, but our patients were
most likely to rank them so. As the potential beneﬁt of
CAM lies mostly in the improved sense of disease control
[19], patients might gain even greater sense of control alter-
ing those aspects of life that are “untouchable” to conven-
tional IBD therapies.
A high-protein diet may be associated with an increased
risk of IBD, while fruit and vegetable intake might decrease
it [20]. Although evidence on the beneﬁt of dietary modiﬁca-
tions in IBD is limited, according to Zallot et al., 58% of IBD
patients believed in the role of diet in relapses and were prone
to avoid certain foods [21]. A Finnish study comparing ado-
lescents with IBD and juvenile idiopathic arthritis reported
self-imposed dietary restrictions in 64.8% of CAM users [13].
Moderate physical activity might complement conven-
tional IBD therapy. Besides improving the individual’s
general well-being and ﬁtness level, regular exercise may
also have beneﬁcial eﬀects on immunological response,
psychological health, nutritional status, and bone mineral
density. Studies suggest potential anti-inﬂammatory eﬀects
of myokines released during skeletal muscle contractions,
but further investigation is needed to clarify the exact
mechanisms [22].
While smoking is generally considered a major environ-
mental risk factor for multiple diseases including vascular
disease, various neoplasia, and chronic obstructive pulmo-
nary disease, evidence proves that smoking cessation might
exacerbate disease activity and symptoms in UC [23]. On
the other hand, it has the opposite eﬀect on CD, as quitting
smoking generally results in decreased disease activity [24].
These eﬀects are also reﬂected in our results: CD patients
were more likely to quit smoking than UC patients.
4.3. Mind/Body Therapies. Besides the psychological burden
associated with IBD (including but not limited to stress in
intimate relationships, worrying over disease complications,
depression, and embarrassment), perceived—especially
prolonged—stress is a signiﬁcant predictor for relapses
[25, 26]. Brief positive eﬀects were reported for health-
related quality of life; nevertheless, identifying the optimal
target of mind/body therapies is also an issue. Berrill et al.
deﬁned irritable bowel syndrome-type symptoms in IBD
as potential therapeutic targets [27]. Jedel et al. identiﬁed a
subgroup of patients with higher stress levels that beneﬁted
from mind/body therapies in terms of disease activity [28].
Despite the promising short-term results regarding relaxa-
tion techniques, evidence is lacking about the feasibility of
mind/body therapies in IBD as maintenance treatment or
prevention of relapses [29, 30].
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4.4. Predictors of CAM Usage. Previous studies associated
female gender, low level of conﬁdence in the physician, and
research of disease-related information with CAM usage,
but no role of disease activity or severity could be determined
[6]. Portela et al. deﬁned steroid prescription (p < 0 001) and
higher education level (p = 0 003) as predictors of CAM
use [7]. According to a population-based case control
study from New Zealand, female gender (p < 0 001), youn-
ger age (p = 0 005), higher education (p = 0 002), higher
income (p = 0 04), being a vegetarian (p < 0 001), and a
middle social class at birth (p = 0 024) were independent
predictors of oral CAM use in IBD unlike disease pheno-
type [31]. Our study conﬁrmed younger age as a predic-
tive factor of lifestyle modiﬁcations, but female gender,
longer disease duration, disease phenotype, and type and
number of conventional medications were not associated
with CAM use.
5. Limitations
The survey was conducted at a tertiary IBD center; thus, data
is not representative of the general population. The control
group of chronic gastrointestinal conditions other than IBD
was rather heterogeneous, and this might result in slight
biases. Cross-sectional design was also a limiting factor, as
well as the fact that not all patients responded to all survey
questions. The survey did not include patient satisfaction
with conventional medication, nor self-evaluated severity
assessment of the disease.
6. Conclusions
Our study revealed that CAM use is relatively common
among IBD patients, especially in terms of lifestyle modiﬁca-
tion (predominantly dietary changes and exercise). Usage
rates of herbs and botanicals were signiﬁcantly lower among
patients with other chronic gastrointestinal disorders, and
IBD patients tended to be more adherent to traditional med-
ication, potentially suggesting a higher level of disease
awareness and trust in conventional remedies. Application
rates of lifestyle modiﬁcations and mind/body therapies were
similar in IBD and other gastrointestinal diseases.
Patients with UC tended to administer herbal products;
the beneﬁcial eﬀect of which is supported by scientiﬁc evi-
dence, whereas no such tendency could be observed in
patients with CD, possibly suggesting less awareness of
potentially useful herbal remedies for CD. Nevertheless, this
did not alter patient satisfaction or adherence to conven-
tional IBD therapy.
High adherence rates to conventional therapy may sug-
gest that patients prefer to use CAM as an adjunction rather
than as a replacement to traditional medicine. However,
there is a need for further studies with a homogenized large
case number investigating the frequency and characteristics
of CAM use in IBD and clarifying the potentially diﬀerent
CAM choices of patients with CD and UC. Still, considering
the high frequency and multiple choices of CAM, physicians
and nurses involved in IBD care should not only be aware of
the most common knowledge about CAM but also be able to
provide appropriate information and guidance to patients in
order to develop high-quality care.
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